Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06579703
PHASE4
Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease
Sponsor: Children's Blood and Cancer Center at Dell Children's Medical Center
View on ClinicalTrials.gov
Summary
Pediatric patients who present with acute vaso-occlusive pain crisis may have equivalent pain reduction scores at lower dosing of intravenous Ketorolac compared to standard dosing of 0.5 mg/kg/dose IV (\<16yo max 15mg, \>16yo max 30mg) x 1 dose.
Official title: Ketorolac Dosing for Acute Vaso-Occlusive Crisis in Pediatric Patients With Sickle Cell Disease
Key Details
Gender
All
Age Range
1 Day - 21 Years
Study Type
INTERVENTIONAL
Enrollment
102
Start Date
2024-09-30
Completion Date
2028-02-15
Last Updated
2024-08-30
Healthy Volunteers
No
Interventions
DRUG
Ketorolac
Randomized to a single dose of: Arm A: 15 mg/mL (per mL) Arm B: 30 mg/mL (per mL)